Validation of the role of apolipoproteins in coronary artery disease patients with impaired kidney function for prognosis: a prospective cohort study in China

Table 3 The subgroup analysis across various kidney functions via Cox regression

	robust HR (95%CI)	P	adjusted HR (95%CI)	P
eGFR ≤ 45 mL/min/1.73m²
continue
ApoB	1.116(0.527–2.361)	0.775	1.226(0.512–2.936)	0.648
ApoA1	0.649(0.304–1.385)	0.263	0.784(0.346–1.775)	0.56
ApoB/ApoA1	1.407(0.631–3.138)	0.404	1.302(0.523–3.238)	0.571
category
ApoB	1.003(0.664–1.456)	0.933	1.108(0.730–1.681)	0.63
ApoA1	0.725(0.484–1.087)	0.119	0.674(0.429–1.058)	0.087
ApoB/ApoA1	1.090(0.662–1.482)	0.961	1.063(0.695–1.658)	0.748
eGFR > 45 mL/min/1.73m²
continue
ApoB	1.686(1.007–2.853)	0.042	1.999(1.131–3.534)	0.017
ApoA1	0.403(0.241–0.673)	0.001	0.391(0.229–0.666)	0.001
ApoB/ApoA1	2.885(1.701–4.893)	0.001	3.090(1.791–5.331)	0.001
category
ApoB	1.313(1.007–1.711)	0.044	1.359(1.027–1.799)	0.032
ApoA1	0.742(0.568–0.968)	0.028	0.728(0.549–0.964)	0.027
ApoB/ApoA1	1.449(1.110–1.889)	0.006	1.511(1.145–1.993)	0.004

Adjusted for sex, age, BMI, ACS, DM, HBP, family history CAD, smoking, Lesion length, MLD, stent, stent length, eGFR, TG, ARB/ACEI, CCB, aspirin, clopidogrel, statin
TG Triglycerides, BMI Body mass index, eGFR Estimated glomerular filtration rate, ACS acute coronary syndrome, DM Diabetes mellitus, MLD Minimal lumen diameter, CAD Coronary artery disease, HBP Hypertension, CCB Calcium channel blockers, ARB/ACEI Angiotensin II receptor blockers/angiotensin-converting enzyme inhibitors

ISSN: 1475-2891